Antengene Files Next-Day Disclosure Return With HKEX on Share RepurchasePUBT·Nov 18, 2026 at 09:42 AM06996-0.40%
Antengene Reports Share Buyback in HKEX Next Day Disclosure ReturnPUBT·Nov 17, 2026 at 09:43 AM06996-0.40%
Antengene Files Next-Day Disclosure Return to HKEX Announcing Share BuybackPUBT·Nov 16, 2026 at 09:39 AM06996-0.40%
Antengene Files Next-Day Disclosure Return With HKEX Announcing Share BuybackPUBT·Nov 12, 2026 at 10:34 AM06996-0.40%
Antengene Reports ATG-207 Efficacy in Preclinical Autoimmune Disease ModelsPUBT·Nov 12, 2026 at 03:12 AM06996-0.40%
Antengene Reports Share Buyback in Next-Day Disclosure to HKEXPUBT·Nov 10, 2026 at 10:20 AM06996-0.40%
Antengene climbs 6% on SITC preclinical data presentationMarket Movers·Nov 10, 2026 at 02:48 AM06996-0.40%
Antengene reports ATG-109 outperforms clinical benchmark in preclinical prostate cancer studyPUBT·Nov 9, 2026 at 12:30 AM06996-0.40%
Antengene Presents Latest Preclinical Results of Novel Cos-TCE Platform AnTenGager‑D2 in Rapid Oral Abstract Presentation at SITC 2026PR Newswire·Nov 9, 2026 at 12:30 AM06996-0.40%
Antengene Corporation Limited Reports Superior Preclinical Efficacy for ATG-109TradingView·Nov 9, 2026 at 12:30 AM06996-0.40%